You're listening to the podcast surgery ICRads. My name's Dr. Jeffrey Guy. I'm an associate

professor of surgery and director of the Burns Center of Vanderbilt University, School of Medicine.

I'm also the editor and author of Pharmacology for the Pre-Hospital Professional. It's available

on Elsevier. Today, the topic that I'd like to take on is the second of two podcasts.

The first one we did was on myocardial infarction of mycardiol ischemia,

and we introduced the basic concepts of myocardialchemia.

I talked about some of the roles of thrombolytics,

and some of the other agents used with thrombolyics,

and then the idea of this second part of the podcast was to discuss some of the role of

procutaneous coronary intervention or PCI.

Now, in the first podcast, we talked about trying to reestablish flow to the Schemic Heart using

various thrombolytic, and we presented some of the advantages and disadvantages of those various agents.

Now, primary coronary intervention, which we'll call PCI, PCI for the main of this podcast,

just to make it easier, and that's what my notes typically say, the major advantages of

primary PCI over thrombilic therapy, include a higher rate of return of normal blood flow.

And this is called Timmy Grade Blood Flow, or Timmy Grade 3. And we discussed that somewhat

in the first podcast. And if you don't understand what Timmy Grade blood flow is, don't worry.

It just really, it's a return of blood flow that is more non-pathological, more of what your typical blood flow is like.

The other advantages of primary PCI is a lower risk of intracranial hemorrhage because we're not using drugs that prevent the formation of blood clot

and an ability to stratify risk based on the severity and distribution of coronary artery disease.

Well, why is it that we can stratify a risk following primary PCI?

Well, it's pretty obvious is that we're able to get a better delineation of what the nature

...